Beik GM
Watt FM
Beik GM
Watt FM
Matrali SSH and Ghag AK
Extended bone fractures or fractures coexisting with bone disorders can lead to non-unions where surgical intervention is required. Composite drug delivery systems are
being used increasingly more in order to treat such defects locally. Alendronate (ALD), a bisphosphonate extensively used in clinical practice to treat conditions such as
osteoporosis has been shown to assist bone fracture healing through its antiresorptive capacity. This study reports the development of a polymeric composite system for the
in situ delivery of ALD, which possesses enhanced encapsulation efficiency (EE%) and demonstrates controlled release over a 70 day period. ALD and calcium phosphate
(CaP) have been incorporated within poly (lactic-co-glycolic acid) (PLGA) microspheres giving rise to a 70% increase in EE% compared to a control system. Finally,
preliminary toxicological evaluation demonstrates a positive effect of the system on pre-osteoblastic cells over 72 hours.
DOI: 10.37421/2157-7552.2021.12.e132
DOI: 10.37421/2157-7552.2021.12.e133
DOI: 10.37421/2157-7552.2021.12.235
DOI: 10.37421/2157-7552.2021.12.e134
Long Thanh Su*, Yoshida Chikako and Nakao Toshihiko
The aim of this study was to compare the plasma cortisol response between the cows after intravaginal insertion of DIB (Dispositivo Intravaginal Bovino) and those after the insertion of CIDR (Controlled Internal Drug Release). Nine ovariectomized cows (four beef and five dairy) were divided into two groups; four cows were inserted with CIDR for 12 days and five cows were treated with DIB for the same period. All the cows did not have any abnormality in the vagina before insertion of the devices. Blood samples were collected via the tail venipuncture once a day at 8:30 to 9:00 for 7 days before treatment and once at 5-10 minutes before insertion, every two hours for 24 hours after the insertion and once daily thereafter until 3 days after removal of the devices. Plasma cortisol concentrations were estimated by an enzyme immunoassay. Mean plasma cortisol concentrations in nine cows for seven days before treatment remained stable. Immediately before the insertion mean of plasma cortisol concentrations in cows treated with CIDR was 3.6 ± 0.6 ng/ml and 2.9 ± 0.7 ng/ml in those treated with DIB. After the insertion, plasma cortisol concentrations increased rapidly (P<0.05), reaching the peak with 8.5 ± 2.5 ng/ml at 4 h (DIB) or 6.4 ± 1.0 ng/ml at 6 h (CIDR) and then gradually decreased to basal levels at 12 h and remained stable thereafter. There was no significant difference in plasma cortisol responses which were marginal and temporal between DIB treated and CIDR treated cows.
DOI: 10.37421/2157-7552.2021.12.e135
DOI: 10.37421/2157-7552.2021.12.e136
DOI: 10.37421/2157-7552.2021.12.237
DOI: 10.37421/2157-7552.2021.12.238
Azadeh Shahroodi, Sogol Hooshyar, Davood Yari, Jebraeil Movaffagh and Ali Moradi*
DOI: 10.37421/2157-7552.2024.15.351
Introduction: Creating an ideal scaffold for bone tissue engineering requires specific characteristics. Composite materials, combining the advantages of polymers and ceramics, offer tailored properties and enhanced functionality. This study aimed to fabricate, characterize and optimize multi-phasic composite scaffolds with spiral backbones for potential bone tissue engineering applications.
Methods: Composite scaffolds were fabricated via electrospinning using 24.5% Zein and varying concentrations of Calcium Phosphate (CP) (15%, 20% and 25%). Ribbon-shaped electrospun Zein/CP composite mats were structured into spiral forms, placed in cylindrical Teflon molds, filled with a blended slurry (Zein/cartilage-derived matrix/CP/gelatin), snap-frozen and lyophilized to form multi-phasic composite scaffolds. Mechanical, FESEM and FTIR analyses assessed compressive strength, architectural properties (porosity, pore size and interconnectivity), thermogravimetric behaviour, chemical functional groups and biocompatibility.
Results and Discussion: The study evaluated composite scaffolds for bone tissue engineering, focusing on varying CP concentrations in Zein nanofibers. The scaffold with a 20% CP concentration exhibited Young’s modulus of approximately 3.26 MPa. FESEM analysis revealed highly interconnected pores for scaffolds with 15% CP, with a pore size of 50.12 ± 6.07 and a porosity of 69.72%. FTIR and DSC analyses confirmed scaffold robustness. Comparisons with bone tissue showed similarities in compressive strength but slight differences in porosity. Despite this, the scaffold demonstrated potential for further optimization. Overall, the scaffold with 20% CP exhibited superior mechanical strength, with larger pore sizes indicating better potential for cell growth and nutrition, high- lighting its promise for bone tissue engineering applications.
DOI: 10.37421/2157-7552.2024.15.361
DOI: 10.37421/2157-7552.2024.15.362
DOI: 10.37421/2157-7552.2024.15.363
DOI: 10.37421/2157-7552.2024.15.364
This paper explores the emerging frontier of regenerative medicine in the context of lung restoration through pluripotent stem cell therapy. By harnessing the transformative potential of pluripotent stem cells, researchers aim to address the limitations of current treatments for lung diseases and injuries. Through a comprehensive review of recent advancements and ongoing research efforts, this abstract highlights the promising prospects, challenges and ethical considerations associated with employing pluripotent stem cell therapy for lung restoration..
DOI: 10.37421/2157-7552.2024.15.365
Cellular therapies utilizing pluripotent stem cells (PSCs) hold promising potential in addressing lung damage and promoting repair. This abstract outlines recent advancements and strategies in employing PSC-derived cells for lung regeneration. We discuss the therapeutic mechanisms, challenges and future directions of PSC-based therapies in lung repair, emphasizing their transformative role in treating respiratory disorders and advancing regenerative medicine.
DOI: 10.37421/2157-7552.2024.15.366
DOI: 10.37421/2157-7552.2024.15.367
Cardiac precision medicine necessitates accurate disease modeling for effective therapeutic development. Leveraging human stem cells, particularly induced pluripotent stem cells (iPSCs), offers a promising avenue for recapitulating cardiac diseases in vitro. This review explores the current advancements, challenges and future prospects of utilizing iPSC-derived cardiomyocytes for disease modeling, highlighting their potential in elucidating disease mechanisms, screening drug candidates and personalizing treatment strategies.
DOI: 10.37421/2157-7552.2024.15.368
DOI: 10.37421/2157-7552.2024.15.369
Journal of Tissue Science and Engineering received 807 citations as per Google Scholar report
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 